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Adiposopathy
Is “Sick Fat” a Cardiovascular Disease?
Harold E. Bays, MD
Louisville, Kentucky
Being overweight or obese is a worldwide epidemic. Adiposity can cause fat mass–related cardiovascular disease
(CVD). Adiposity may also cause adipocyte and adipose tissue anatomic and functional abnormalities, termed adipos-
opathy (adipose-opathy) or “sick fat,” that result in endocrine and immune derangements. Adiposopathy may directly
contribute to CVD through pericardiac and perivascular effects on the myocardium and blood vessels. Adiposopathy
may also indirectly contribute to CVD through promoting or worsening major CVD risk factors such as type 2 diabetes
mellitus, high blood pressure, and dyslipidemia. Despite CVD being the most common cause of mortality among over-
weight individuals, the pathophysiologic relationship between adiposity and CVD is often thought mysterious, as evi-
denced by “obesity paradoxes.” Underlying this uncertainty are suggestions that excessive body fat does not always
increase the risk of CVD and, in some cases, may actually decrease such risks. These paradoxical findings are made
less paradoxical when the pathogenic potential of excessive body fat is assessed based on adipose tissue dysfunction
rather than simply on increased fat mass alone. This introductory review 1) provides a brief historical perspective of
the pathogenic potential of adipose tissue; 2) describes the relationships between adipose tissue (histology, embryol-
ogy, and adipogenesis) and cardiovascular medicine; 3) outlines the anatomic, functional, endocrine, and immune
manifestations of adiposopathy; and 4) describes the importance of cross talk and/or interactions of adipose tissue
with other body tissues. Finally, this review describes how “sick fat” helps account for various clinical obesity/cardio-
vascular paradoxes, supporting adiposopathy as a cardiovascular disease. (J Am Coll Cardiol 2011;57:2461–73)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.038Adiposity is excessive adipose tissue. Those with adiposity
are characterized as being overweight or obese. Obesity is
described as an independent risk factor for cardiovascular
disease (CVD) (1). Adiposity is pathological to the cardiovas-
cular system through excessive fat-mass mechanisms and
through adipocyte and adipose tissue dysfunction (2) (Table 1,
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adipose tissue anatomic/functional disturbances promoted by
positive caloric balance in genetically and environmentally
susceptible individuals that result in adverse endocrine and
immune responses that may directly promote CVD, and may
cause or worsen metabolic disease. Because many of these
metabolic diseases are major CVD risk factors (e.g., type 2
diabetes mellitus [T2DM], high blood pressure, and dys-
lipidemia), adiposopathy also indirectly increases CVD risk
(3–6) (Table 2, Fig. 1) This review examines the relation-
ship between pathogenic adipose tissue, CVD, and CVD
risk factors.
Adiposopathy: A Historical Perspective
Despite the known relationship between adiposity and
metabolic disease (5), perceptions have lagged for decades in
acknowledging the pathologic potential of adipose tissue.
As early as the 1940s, reports described visceral adiposity as
increasing the risk of metabolic disease and CVD in men
(7). Reports from subsequent decades also supported the
pathogenic potential of adipose tissue (8,9), and identified
excessive adipocyte hypertrophy as promoting metabolic
disease (10,11). However, as late as the 1980s, the relation-
ship between adiposity and metabolic disease remained
elusive, as evidenced by the haunting term syndrome X,
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wording, but also confusing be-
cause it represented only 1 of
about 20 terms describing a sim-
ilar relationship (3,12). Ulti-
mately, the term metabolic syn-
drome was generally agreed upon
to describe a common clustering
of CVD risk factors that in-
cluded increased waist circumfer-
ence as a diagnostic criterion.
Even then, different international
scientific organizations had differ-
ent diagnostic criteria for the met-
abolic syndrome (13–15). Further-
more, in 2005, the American
Diabetes Association and the Eu-
ropean Association for the Study
of Diabetes issued a joint state-
ment questioning the clinical utility of the term metabolic
syndrome (16). Among reasons for the skepticism of this term
were 1) metabolic syndrome did not reflect a unified, patho-
physiologic process leading to clustering of metabolic disorders;
2) the diagnostic criteria was predominantly based on U.S. and
European data, which did not necessarily apply to other
populations (e.g., Asians) (3); 3) and the diagnosis of the
metabolic syndrome did not appear to be a better predictor of
future metabolic disease than the assessment of its individual
components (17).
In the early to mid-2000s, concurrent with debates
involving metabolic syndrome (18,19), was the undercurrent
of mounting evidence supporting (“confirming”) the meta-
bolic components of the metabolic syndrome as being due to
an underlying, unified pathophysiologic process (20). De-
cades of research supported adipose tissue pathology as
relevant to a “common soil” hypothesis (21). These findings
were consistent with the National Education Program,
Adult Treatment Panel III guidelines in which an increased
waist circumference (a surrogate for subcutaneous abdomi-
nal and visceral adipose tissue) was the only organ-
associated, anatomic diagnostic criteria for metabolic syn-
drome (with other metabolic syndrome components being
elevated glucose levels, high blood pressure, hypertriglycer-
idemia, and reduced high-density lipoprotein cholesterol
levels) (22). Furthermore, although the National Education
Program, Adult Treatment Panel III deemed 3 of any of
these 5 components as diagnostic for metabolic syndrome,
the International Diabetes Federation further validated the
importance of pathogenic adipose tissue by designating
increased waist circumference/central obesity as the only 1
of 5 criteria required for the diagnosis of metabolic syn-
drome (23), which then must be accompanied by other
metabolic abnormalities.
It was through decades of adipose tissue scientific re-
search and the acknowledgment of the importance of central
Abbreviations
and Acronyms
BMI  body mass index
CVD  cardiovascular
disease
ECM  extracellular matrix
ER  endoplasmic
reticulum
PPAR  peroxisome
proliferator-activated
receptor
SAT  subcutaneous
adipose tissue
T2DM  type 2 diabetes
mellitus
VAT  visceral adipose
tissueadiposity by major scientific organizations that the termadiposopathy arose (3). Cardiomyopathy describes the
pathologic enlargement of heart cells and the heart organ,
which results in anatomic/functional abnormalities leading
to adverse clinical consequences. Similarly, adiposopathy
describes the pathogenic enlargement of fat cells and fat
tissue, which results in anatomic/functional abnormalities
leading to adverse clinical consequences, including the most
common metabolic diseases encountered in clinical practice
(e.g., T2DM, high blood pressure, dyslipidemia) (24).
Given that adipose tissue has no less potential for disease
than any other body organ, the term adiposopathy is
intended to identify adipose tissue organ pathology similar
to the “opathies” of multiple other body organs (6). From a
clinician standpoint, recognizing the pathogenic potential of
adipose tissue may afford a clearer rationale toward recom-
mending weight reduction to overweight patients. In other
words, discussing how fat weight gain causes fat to become
“sick” and how losing body weight causes fat to become
more “healthy” might prove to be more productive than
discussing the individual diagnostic components defining
the metabolic syndrome (6).
Adipose Tissue Histology, Anatomy,
Embryology, and Adipogenesis
As with other body organs, adipose tissue anatomy and
functionality are interrelated. The reported histological
composition of adipose tissue is dependent on 1) individual
characteristics, such as age, race, sex, genetics, environment,
caloric balance, ingested food content, and physical activity;
2) the origin or location of the adipose tissue being analyzed;
Examples of Adiposity and AdiposopathyDisorder Related to C rdiovascular DiseaseTable 1 Examples of Adiposity and AdiposopathyDisorders Related to Cardiovascular Disease
Adiposity-related*
Sleep apnea
Thromboembolic events
Increased blood volume
Increased cardiac output
Atrial enlargement
Ventricular dilation
Electrocardiogram abnormalities: increased heart rate, increased PR interval,
increased QRS interval, decreased QRS voltage (although sometimes
increased), increased QTc interval, abnormal signal-averaged
electrocardiogram late potentials, ST–T-wave abnormalities, left-axis
deviation, criteria for left ventricular hypertrophy, flattening of the T waves
(inferolateral leads), left atrial abnormalities, and false positive criteria for
inferior myocardial infarction
Adiposopathy-related*
Type 2 diabetes mellitus
High blood pressure
Dyslipidemia
Metabolic syndrome
Atherosclerosis
Cardiomyopathy (“fatty heart”)*In some cases, the listed disorders may have both adiposity and adiposopathy-related
components.
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aspiration or excisional biopsy) (25).
Adipocytes typically constitute the majority of adipose
tissue cellular content. Fat-containing adipocytes constitute,
by far, most of the adipose tissue volume. Adipocytes are
surrounded by fibrous connective tissue, collagen, nerves,
and blood vessels (1). Adipose tissue’s supporting frame-
Figure 1 Adiposopathy: Simplified Relationship Between Patho
Adiposopathy is promoted by unhealthy nutrition and a sedentary lifestyle in genet
peripheral, subcutaneous adipose tissue during positive caloric balance, existing f
deposited in nonadipose tissue organs (e.g., liver, muscle, possibly pancreas) res
pathogenic to the cardiovascular system or otherwise interact with other body sys
or promote major atherosclerotic risk factors (type 2 diabetes mellitus, high bloodwork contains “stromal vascular fraction” cells, which in-clude mesenchymal cells, fibroblasts, preadipocytes, endo-
thelial precursor cells, smooth muscle cells, blood cells, and
immune cells.
Adipose tissue–associated mesenchymal cells are espe-
cially applicable to cardiovascular medicine because cardio-
vascular and adipose tissue cells share a common lineage.
After fertilization of the ovum and mitotic divisions of the
Adipose Tissue and Cardiovascular Disease
nd environmentally predisposed individuals. With impaired adipogenesis of
s may hypertrophy, circulating free fatty acids may increase, and lipids may be
in lipotoxicity. Adiposopathic endocrine and immune responses may be directly
If not mitigated by these other body organs, adiposopathy may indirectly cause
ure, or dyslipidemia). Figure illustration by Craig Skaggs.genic
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derm may differentiate into hematopoietic tissue, kidney,
and sex organs, as well as mesenchymal stem cells (Fig. 2).
Mesenchymal stem cells may differentiate into skeletal
myoblasts, osteoblasts, chondroblasts, tenoblasts, marrow
stromal cells, neuron-like cells, and importantly, into cardi-
omyocytes, angiocytes, and adipocytes (26). Thus, adipose
tissue is a rich, nonembryonic source of mesenchymal cells
(27) whose relative ease in accessibility and capacity for
differentiating into heart and blood vessel cells have medical
applications to CVD regenerative medicine, tissue engi-
neering, and cell replacement therapies and represents a
potential therapeutic modality to repair post-ischemic or
infarcted heart tissue (28).
Beyond cardiovascular and adipose cells having common
stem cell origins, once mesenchymal stem cells are committed
to adipocyte formation, adipogenesis itself has relevance to
CVD. Previously, adipogenesis was thought to cease early in
Adiposopathy (“Sick Fat”): Summaryof Causality and Examples of Anatomic,Path physiological, and Clinical Manifestations*
Table 2
Adiposopathy (“Sick F t”): Summary
of Causality and Examples of Anatomic,
Pathophysiological, and Clinical Manifestations*
Causes of adiposopathy
Positive caloric balance
Sedentary lifestyle
Genetic predisposition
Environmental causes
Anatomic manifestations of adiposopathy
Adipocyte hypertrophy
Visceral, pericardial, perivascular, and other periorgan adiposity
Growth of adipose tissue beyond its vascular supply
Increased number of adipose tissue immune cells
“Ectopic fat deposition” in other body organs
Pathophysiological manifestations of adiposopathy
Impaired adipogenesis
Pathological adipocyte organelle dysfunction
Increased circulating free fatty acids
Pathogenic adipose tissue endocrine responses (e.g., increased leptin,
increased tumor necrosis factor-alpha, decreased adiponectin, and
increased mineralocorticoids)
Pathogenic adipose tissue immune responses (e.g., increased
proinflammatory responses through increased tumor necrosis factor-alpha
and decreased anti-inflammatory responses through decreased
adiponectin)
Pathogenic interactions or pathogenic cross talk with other body organs
(e.g., liver, muscle, and central nervous system)
Clinical manifestations of adiposopathy
Hyperglycemia
High blood pressure
Dyslipidemia
Metabolic syndrome
Atherosclerosis
Fatty liver
Hyperandrogenemia in women
Hypoandrogenemia in men
Cancer
*Adiposity can result in both fat-mass pathology and fat dysfunctional abnormalities resulting in
adiposopathy.life, resulting in a fixed number of adipocytes that predestinedindividuals to be lean or obese. However, fat-cell turnover is
now known to be a dynamic process by which mesenchymal
stem cells undergo lineage commitment, pre-adipocyte prolif-
eration, growth arrest, and terminal differentiation into mature
adipocytes. The number of adipocytes is therefore dependent
on the balance between adipogenesis and apoptosis (29,30),
ith some suggesting that approximately 10% of fat cells are
enewed annually at all adult ages and at all levels of body mass
ndex (BMI) (31).
This has clinical implications because during positive
aloric balance, adipocytes normally undergo initial hyper-
rophy, which elicits cellular signaling for the recruitment,
roliferation, and differentiation of new fat cells. If adipo-
enesis proceeds unencumbered in peripheral subcutaneous
dipose tissue, then adiposity may not cause demonstrable
dipose tissue dysfunction or adverse metabolic conse-
uences. Conversely, if adipogenesis is impaired, then the
ack of adipocytes to adequately proliferate (or differentiate)
ay be pathophysiologically analogous to a relative lack of
dipocytes, sometimes described as representing an acquired
ipodystrophy (32). The lack of excess energy storage in new
at cells due to inadequate adipogenesis may cause existing
at cells to undergo excessive hypertrophy, causing adipocyte
ysfunction and pathogenic adipocyte and adipose tissue
ndocrine and immune responses (2) (Tables 3 and 4).
The concept of adipocyte hypertrophy during positive
caloric balance representing a failure of adipocytes to ade-
quately proliferate (32) is supported by findings that T2DM
is associated with a decrease in adipogenic gene expression
(34) and that T2DM patients have larger adipocyte size but
decreased adipocyte cellularity compared with obese pa-
tients without T2DM (35). In short, if during positive
caloric balance, any stage of the adipogenic processes is
impaired (recruitment, proliferation [36] or differentiation
[35,37,38]), then this may lead to pathologic adipose tissue
endocrine and immune responses that contribute to meta-
bolic disease, particularly in individuals who are genetically
or environmentally predisposed (2) (Fig. 1).
Fat Depots
The clinical importance of adiposity is not only how fat is
stored (i.e., adipocyte proliferation vs. adipocyte hypertro-
phy), but also where fat is stored. Visceral adipose tissue
(VAT) may be more metabolically active than subcutaneous
adipose tissue (SAT), and these depots inherently differ in
processes involving lipolysis/lipogenesis, expression of adi-
pocyte receptors, and differ in the secretion of adipokines/
cytokines, enzymes, hormones, immune molecules, pro-
teins, and other factors (2). Derangements in adipose tissue
endocrine and immune processes contribute to metabolic
disease (4).
Fat depots other than VAT have pathogenic potential
(39,40). Pericardial, subcutaneous abdominal, perimuscular,
perivascular, orbital, and paraosseal fat depots also have lipo-
lytic and inflammatory activities (2). Pericardial and perivascu-
2465JACC Vol. 57, No. 25, 2011 Bays
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myocardium, coronary arteries, and peripheral vessels via dys-
regulated local secretion of vasoactive and inflammatory factors
that may contribute to atheroma instability and other cardio-
vascular pathophysiology (41–45). Pericardial adiposity is
strongly associated with coronary atherosclerosis in African
Americans with T2DM, which may contribute to ethnic
disparities in atherosclerosis susceptibility (46). Finally, al-
though often assumed that atherosclerosis is exclusively an
intraluminal, subendothelial, lipid-mediated process, patho-
genic pericardial and perivascular adipose tissue may directly
contribute to atherosclerosis through an “outside to inside”
Figure 2 Simplified Diagram of the Common Embryonic Origin o
Through the formation of mesenchymal stem cells, cardiomyocytes, angiocytes, aninflammatory atherogenic model (41–43), which is againsupported by the strong association between pericardial adipose
tissue and coronary artery calcification (47).
Extracellular Matrix Remodeling,
Angiogenesis, and Hypoxia
In addition to how fat is stored and where fat is stored, other
determinants of the pathogenic potential of expanding
adipose tissue include the interdependent physiologic pro-
cesses of angiogenesis and extracellular matrix (ECM)
remodeling (2). If an increase in fat storage results in
excessive adipocyte enlargement, then adipocyte hypertro-
rt, Blood Vessels, and Adipose Tissue
ocytes share a common genetic lineage. Figure illustration by Craig Skaggs.f Hea
d adipphy may contribute to intracellular hypoxia (48,49). Addi-
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a relative lack of blood flow may result in both cellular and
adipose tissue hypoxia (49,50). As with other body tissues
(e.g., heart), cellular and tissue adipose hypoxia contributes
to cellular and organ dysfunction (51), contributes to pro-
inflammatory responses, and all may contribute to the onset
or worsening of metabolic disease (52). For example, if
periadipose ECM remodeling is impaired due to relative
hypoxia or other adipocyte dysfunction, then further fat
storage may be physically limited, resulting in increased
circulating free fatty acids and lipotoxicity. Furthermore,
hypoxia-driven inflammation may promote ECM instability
(53), and excessive synthesis of ECM components may
impose long-term interference with cell–cell contact and
adipogenic signaling mechanisms, and thus persistent ad-
verse cellular responses even after weight loss (54).
Free Fatty Acids and Lipotoxicity
If during positive caloric balance, adipocytes are unable to
store excess energy (mostly in the form of triglycerides),
then circulating free fatty acids are increased, causing
pathologic disruption of nonadipose tissue organs, such as
the liver, muscle, pancreas, and blood vessels. Potential
adverse metabolic consequences of lipotoxicity (55) include
abnormalities of glucose and lipid metabolism (5,56), and
high blood pressure (57).
Although VAT is most recognized as a contributor to
metabolic disease, the majority of circulating free fatty acids
actually originates from SAT, mainly because SAT is the
largest fat depot, constituting 80% or more of total body
fat. Even within large vessel drainage of VAT (which
Adipose Tissue as an Endocrine Organ:cytes and Adipose Tissue Produce Factorsctivel Involved in Metabolic Process sImportant for Human H lth*
Table 3
Adipose Tissue as an Endocrine Organ:
Adipocytes and Adipose Tissue Produce Factors
Actively Involved in Metabolic Processes
Important for Human Health*
Angiogenesis
Adipogenesis
Extracellular matrix dissolution and reformation
Lipogenesis
Growth factor production
Glucose metabolism
Production of factors associated with the renin-angiotensin system
Lipid metabolism
Enzyme production
Hormone production
Steroid metabolism
Immune response
Hemostasis
Element binding
Adipose tissue has receptors for traditional peptides and glycoprotein hormones,
receptors for nuclear hormones, other nuclear receptors, receptors for
cytokines or adipokines with cytokine-like activity, receptors for growth
factors, catecholamine receptors, and other receptors.
Data from Bays et al. (2) and Bays et al. (33). *Disruption of adipose tissue endocrine function may
contribute to metabolic disease.sometimes constitutes 20% of body fat), the majority of
l
Vfree fatty acids in the portal system may originate within
SAT (38,58), which may contribute to lipotoxic effects on
the liver, with adverse clinical consequences such as hyper-
glycemia and dyslipidemia (4). So while VAT is generally
considered among the most pathogenic fat depots (2,59,60),
if SAT fat storage is limited or impaired during positive
caloric balance and if SAT net free fatty acid release is
increased into the circulation, then this SAT dysfunction
may adversely affect nonhepatic organs (59,60), resulting in
lipotoxicity to muscle (causing insulin resistance) and the
pancreas (possibly reducing insulin secretion) (2,61,62).
Adipose Tissue as an Active Endocrine
and Immune Organ
Excessive adipocyte hypertrophy disrupts the normal phys-
iological function of fat-cell organelles (causing adipocytes
to become “sick”), as evidenced by increased markers of
intracellular endoplasmic reticulum (ER) stress and mito-
chondrial dysfunction (49,63,64). The ER is a network of
interconnected tubules, vesicles, and cisternae that, among
other functions, produce protein and lipids and transport
proteins and carbohydrates necessary for normal cellular
function. Increased markers of adipocyte ER stress are
associated with inflammation, cellular dysfunction, and
metabolic disease (65). Mitochondria are membrane-
enclosed organelles that contain enzymes responsible for
Adipose Tissue as an Immune Organ:cytes and Adipose Tissue Produce Factorsctivel Involved in Im unological ProcessesImportant for Human H alth*
Table 4
Adipose Tissue as an Immune Organ:
Adipocytes and Adipose Tissue Produce Factors
Actively Involved in Immunological Processes
Important for Human Health*
Pro-inflammatory adipose tissue factors
Factors with cytokine activity include adipsin, IL-1B, IL-6, IL-8, IL-17D, IL-18,
leptin, MCSF-1, MCP-1, MMIF, resistin, tumor necrosis factor-alpha,
RANTES, VASPIN
Acute phase response proteins include AGP, ceruloplasmin, C-reactive protein,
haptoglobin, IL-1RA, lipocalins, metallothionein, pentraxin-3, PAI-1, and
serum amyloid A
Proteins of the alternative complement system include adipsin, ASP,
complement C3 and B
Chemotactic/chemoattractants for immune cells include eotaxin,
interferon inducible protein, MCSF-1, MCP-1, MMIF, RANTES, resistin,
stromal-derived factor 1, VAP-1, and VCAM-1
Eicosanoids/prostaglandins such as prostaglandin E2
Anti-inflammatory adipose tissue factors
Adiponectin
Annexin-1
IL-6 and -10
Transforming growth factor-beta
Bone morphogenic factor
Nitric oxide
IL-1 receptor antagonist
*Adipose inflammatory factors are produced by adipocytes and adipose tissue-associated macro-
phages. An increase in adipose tissue inflammatory response and a decrease in anti-inflammatory
response may contribute to metabolic disease.
AGP  alpha-1 acid glycoprotein; ASP  acylation-stimulating protein; IL  interleukin; MCP 
monocyte chemoattractant protein; MCSF  macrophage colony-stimulating factor; MMIF 
macrophage migration inhibitory factor; PAI  plasminogen activator inhibitor; RANTES  regu-
ated on activation, normal T-cell expressed and secreted; VAP  vascular adhesion protein;
ASPIN  visceral adipose tissue–derived serpin; VCAM  vascular cell adhesion molecule.
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production of adenosine triphosphate. Increased markers of
adipocyte mitochondrial stress are associated with obesity,
insulin resistance, and T2DM (66).
Among the adverse consequences of adiposity-induced
“sick fat” (5,6) is a disruption of physiological endocrine (6)
and immune function (39), which, in turn, contributes to
metabolic disease (2,67–69). The mechanisms by which
adiposopathic endocrine and immune responses contribute to
T2DM, high blood pressure, dyslipidemia, and other meta-
bolic disorders (4,5), and mechanisms explaining how nutri-
tion, physical activity, drug therapies, and bariatric surgical
interventions improve metabolic disease (33,70–74) are be-
yond the scope of this discussion. Nonetheless, Tables 3 and 4
ist examples of adipose tissue endocrine and immune func-
ions whose disruption may contribute to metabolic disease.
dipose Tissue Cross Talk and Interactions
ith Other Body Organs
misconception of an adipocentric paradigm is that it fails
o account for the pathophysiological role of nonadipose
rgans. Although adipocyte and adipose tissue dysfunction
re often etiologic, adiposopathy alone does not cause or
orsen metabolic disease. Instead, the clinical consequences
f “sick fat” depend on how adipose tissue interacts or
ndergoes “cross talk” with other body organs such as the
iver, muscle, pancreas, as well as organs of the cardiovas-
ular, endocrine, immune, nervous, genitourinary, gastroin-
estinal, integumentary, and other body systems (5).
T2DM, high blood pressure, and dyslipidemia often have
efined causes (3) (Table 5). However, the exact “cause” of
ost instances of these metabolic diseases are ill defined.
hat is well defined is that the prevalence of these major
Examples of Diseases Other Than AdiposopathyTh t Cause Common Metabolic DiseaseTable 5 Exa pl of Diseases Oth r Th n AdiposopathyThat Cause Common Metabolic Diseases
Type 2 diabetes mellitus
Hemochromatosis
Chronic pancreatitis
Hypercortisolism
Excessive growth hormone
Genetic syndromes of insulin resistance
Genetic syndromes of decreased pancreatic function
High blood pressure
Pheochromocytoma
Primary hyperaldosteronism
Hypercortisolism
Hyperthyroidism
Renal artery stenosis
Various kidney diseases
Familial or genetic syndromes
Dyslipidemia
Untreated hypothyroidism
Poorly controlled diabetes mellitus
Certain types of liver or kidney diseasesf
Genetic dyslipidemiasardiovascular risk factors markedly increase with increasing
ody weight (5). The accumulation of adipose tissue (adi-
osity) and dysfunctional adipose tissue (adiposopathy)
ontributes to most, if not all, cardiometabolic risk factors
75). Recognizing the pathogenic potential of adipose tissue
ot only helps describe the relationship between adiposity
nd metabolic disease, but also provides a scientific founda-
ion as to why treatment of adiposopathy often improves
etabolic disease (73). This concept also helps validate the
emerging concept is that the development of anti-obesity
gents must not only reduce fat mass (adiposity) but must
lso correct fat dysfunction (adiposopathy)” (76).
In but 1 example, adiposopathy increases circulating free
atty acids. If the liver and muscle are “inflexible” (limited)
n their ability to metabolize increased free fatty acid influx,
hen this may cause “lipotoxic” intraorgan and intracellular
ccumulation of lipid metabolites (e.g., fatty acyl coenzyme
, diacylglycerol, ceramide), which contributes to insulin
esistance (2,55). The pancreas and arterial tissues maybe
dversely affected as well, possibly causing beta-cell dys-
unction and accelerated atherosclerosis, respectively
55,77). In fact, “inflexible” intraorgan triglyceride concen-
ration may distinguish obese individuals in whom meta-
olic abnormalities develop from obese individuals in whom
one develop (78).
Conversely, if organs such as the liver are able to
vercome lipotoxicity through inherent hyperflexibility or
hrough the use of therapeutic agents such as peroxisome
roliferator-activated receptor (PPAR) gamma agonists
2,55), then the onset or worsening of metabolic disease
ay be mitigated. Some investigators suggest that if adi-
osity occurs without intraorgan (e.g., intrahepatic) fatty
nfiltration, then the onset or worsening of metabolic
isease may be averted (79). They conclude that 1) the
haracteristics of adipose tissue are more important than the
mount of body fat in determining the risk of obesity-
elated metabolic disease; 2) insulin resistance is associated
ith increased fat-cell size, increased adipose tissue lipolytic
ctivity, adipose tissue inflammatory cell infiltration, adi-
ose tissue hypoxia, and adipose tissue ER stress; and 3) the
ccumulation of ectopic fat in other organs, particularly the
iver, might be a marker of adipose tissue pathology (79), as
ight occur in patients with adiposopathic responses to
ositive caloric balance.
diposopathy and Aging
rrespective of age, adiposopathy increases the prevalence of
etabolic disease and CVD risk factors (80,81). However,
diposopathy and aging share analogous pathophysiologies.
rom a cellular standpoint, both adiposopathy and aging
an increase markers of intracellular ER stress and mito-
hondrial dysfunction (49,63–66,82–84), and both are as-
ociated with impaired adipogenesis (2,85). From a clinical
tandpoint, both adiposopathy and aging: 1) are risk factors
or CVD, T2DM, high blood pressure, and dyslipidemia;
2468 Bays JACC Vol. 57, No. 25, 2011
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acids (86) and reduced testosterone levels in men (87,88);
and 3) both may promote immunopathies such as increased
C-reactive protein (2,89). When stratified based on age and
BMI, the relationship between adiposopathy and aging is
complex, as evidenced by the variable association of meta-
bolic syndrome components (90). Adverse oxidative reac-
tions are also shared by adiposopathy (91) and aging (92).
Oxidation creates unstable oxygen free radicals and other
reactive oxygen species that create biomolecular instabilities
toxic to cells. If reactive oxygen species production exceeds
a biological system’s ability to detoxify them, then this
“oxidative stress” may contribute to metabolic disease and
atherosclerosis (91).
Adiposopathy as a Conceptual Resolution
of the Obesity Paradox
Various obesity paradoxes are described when increased
body fat mass does not increase morbidity or mortality,
when a decrease in excessive body fat does not improve
patient health, or when an increase in body fat mass actually
reduces morbidity or mortality. Many of these apparent
clinical contradictions are mitigated if the pathogenic po-
tential of excess adipose tissue is assessed not solely by
adiposity, but also by adiposopathy.
Not all obesity paradoxes are due to adiposopathy (93).
However, many obesity paradoxes are less paradoxical if
adipose tissue is accepted as being more than an inert
storage organ. For example, not all overweight patients
develop metabolic disease and not all patients with meta-
bolic disease are overweight (5). This paradox is best
explained when understanding that fat weight gain most
often contributes to the onset or worsening of metabolic
disease when accompanied by pathogenic adipocyte and
adipose tissue anatomic, endocrine, and immune responses
in genetically and environmentally susceptible patients
(2,4,5,39,94). This also helps explain paradoxical popula-
tions described as “metabolically healthy, but obese” (95),
“metabolically obese, normal weight” (95), and the increased
risk of T2DM among Pima Indians (2,96). Adiposopathy
also helps explain the otherwise curious (paradoxical) use of
“ectopic fat” to describe excessive fat deposition in any body
organ, including increased fat deposition in fat depots (e.g.,
visceral adipose tissue) (55,73,97), and helps identify when
adiposity or obesity might best be considered a disease
(6,98,99).
Cardiovascular risk paradox. The susceptibility to adipos-
opathy provides an explanation for the high prevalence of
T2DM, the metabolic syndrome, and CVD among Asians,
particularly those from the South and East Asian subcon-
tinent (2,3). Asian Indians have an increased adipocyte size,
fewer adipocytes (100,101), increased visceral adiposity
(102), increased circulating free fatty acids (103), increased
leptin levels (103,104), increased pro-inflammatory factors
(e.g., increased C-reactive protein levels) (105), and de-creased anti-inflammatory factors (e.g., decreased adiponec-
tin) (103,104), which lead to increased insulin resistance
(103) and increased CVD risk (106). Genetic susceptibility
helps account for the common clinical finding that many
patients of Asian descent have metabolic disease, even when
not markedly overweight (100). This has prompted inter-
national organizations to suggest that Asians should have
different cutoff points for the determination of overweight
and obesity (107).
Similarly, adiposopathy helps explain why, for the same
age and weight, men have higher rate of CVD compared
with women. During positive caloric balance, men often
expand lower body fat through the more pathogenic process
of adipocyte hypertrophy, whereas women typically undergo
the less pathogenic process of adipocyte hyperplasia (108).
Furthermore, men often store excessive fat in an “android”
or “apple” (i.e., visceral) distribution, whereas women often
store fat in a “gynoid” or “pear” (i.e., peripheral subcutane-
ous) distribution. These differences in adipose tissue expan-
sion and fat depot accumulation may help explain the sex
paradox (109), in which, when corrected for various demo-
graphic factors (such as age), men have higher CVD risk
than women (2,7,29,110).
Finally, it is clinically relevant that not all body fat gain
worsens cardiovascular risk or risk factors. Benign multiple
symmetrical lipomatosis is manifest by increased fat accu-
mulation in the SAT regions of the arms, legs, shoulders,
and neck. Despite adiposity, typically glucose or lipid
disorders do not develop in patients, a finding most likely
due to increased proliferation of small adipocytes in SAT
and the increased secretion of anti-inflammatory adipo-
kines, such as adiponectin (111).
Cardiovascular event and cardiac procedure paradox. Mod-
estly overweight individuals may live longer than those who
weigh less (112), possibly because patients with reduced
body weight often have illnesses with high mortality (e.g.,
chronic heart disease, cancer) (113). However, studies have
consistently suggested that modestly overweight patients
have reduced morbidities and mortality after diagnosis of
CVD, after experiencing a CVD event, and/or after under-
going CVD procedures (114–122).
This CVD paradox may be risk factor dependent. Re-
garding the CVD risk factor of sedentary lifestyle, over-
weight and obese men may have increased longevity only if
they are physically fit (123). Cigarette smoking reduces body
weight, but is a major CVD risk factor. CVD patients who
smoke have an increase in all-cause mortality compared with
those who quit smoking (124), especially if they have
chronic lung disease, which would tend to further decrease
body weight (117). Thus, despite lower body weight in
cigarette smokers, their CVD risk is increased. Patients with
chronic heart failure may have no survival benefit with
obesity if they have the major CVD risk factor of T2DM
(125). Most CVD patients have “normal” or only modest
elevations in cholesterol (another CVD risk factor) (126),
yet have a high prevalence of other adiposopathy-associated
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with the adiposopathy-related CVD risk factors may be
more frequent, the morbidity and mortality associated with
nonadiposopathy-related CVD pathology may be more
clinically adverse. In other words, many patients with
genetic dyslipidemias (e.g., familial hypercholesterolemia)
are not overweight, yet have a disproportionately high rate
of premature cardiovascular morbidity and mortality. Thus,
although adiposopathy-induced CVD may be more com-
mon, the morbidity and mortality with nonadiposopathy-
induced CVD may be much worse. Finally, mortality
among those with CVD is directly associated with central
obesity and inversely associated with BMI (128). Given that
central or visceral adiposity is an anatomic manifestation of
“sick fat,” this supports the concept that adiposopathy may
be a more rational treatment target than adiposity alone
(129).
Yet another potential explanation of the CVD risk/
obesity paradox is that establishing an independent relation-
ship between adiposity and CVD is challenging because of
the confounding effects of covariants, comorbidities, and
concomitant drug treatments (130). Due to adiposity-
related illnesses, overweight patients may receive more
frequent medical care and have greater access to global
preventive care, which may reduce morbidity and mortality.
Many overweight patients have metabolic diseases that
prompt treatment with metabolic drug treatments proven to
reduce CVD morbidity and, in some cases, treatments
proven to reduce cardiac and overall mortality (131). For
example, the extent to which reducing hyperglycemia in
T2DM reduces atherosclerotic cardiovascular events is un-
clear (5). However, patients with T2DM are not only
treated with glucose-lowering therapies, but often aggres-
sively treated with antihypertensive, lipid-altering, and even
antithrombotic therapies that conceivably reduce cardiovas-
cular morbidity and mortality relative to matched nonover-
weight patients without T2DM, many of whom may not be
treated with such agents.
Finally, adiposity may be associated with enhanced car-
diovascular autoreparative potential. Overweight individuals
may have greater availability of adipose tissue-associated
mesenchymal cells that upon release, could conceivably reduce
CVD morbidity. After an acute CVD event, reparative circu-
lating mesenchymal cells (originating from tissues such as
adipose tissue, bone marrow, and blood vessels) (Fig. 2)
igrate to the injured myocardial site (132,133). In their
aïve state, adult stem cells may have a limited reparative
enefit in patients with ischemic heart disease. Pre-emptive
ineage pre-specification through guided cardiopoiesis may
e needed to optimize therapeutic outcomes (134). Adipos-
ty signaling promotes the recruitment of adipocytes from
dipose tissue-associate mesenchymal cells (135). Thus, the
resence of adiposity may promote an increased number of
rogenitor cells available for mobilization into the circula-
ion and potentially enhance adipose tissue mesenchymal
ifferentiation into cells more apt to undergo either cardio-poiesis or adipogenesis (i.e., not yet solely committed to
adipogenesis). If so, then an increase in the circulatory
release of mesenchymal cells during cardiac injury (or
possibly cardiac procedures) might have a greater potential
for cardiovascular autorepair. Supporting this mechanism is
that abnormally expanded fat tissue increases the mobiliza-
tion of endothelial progenitor cells, which may have a
protective effect against vascular atherosclerosis in obese
patients (136).
Fat gain and fat loss cardiovascular risk factor paradox.
From a cardiovascular treatment standpoint, a paradoxical
clinical scenario is adding fat as a means to treat diseases
often associated with too much fat (33). PPAR-gamma
agonists increase the recruitment, proliferation, and differ-
entiation of functional fat cells in SAT relative to VAT
(2,54,70). Increased adipogenesis helps account for how
PPAR-gamma agents increase body fat, improve adipocyte
function, lower glucose levels in patients with T2DM,
reduce heptatic steatosis (55,137), and helps explain how
some PPAR gamma agents improve lipid parameters (138)
and potentially reduce CVD risk (139).
Adiposopathy also helps explain why not all body fat loss
improves cardiovascular risk factors. Inherited lipodystrophy
is characterized by a variable lack of body fat and impaired
adipose tissue function (e.g., low adiponectin levels and
inability to adequately store fat). Because of limited fat
storage potential, lipodystrophic patients have high circu-
lating free fatty acids that contribute to lipotoxicity and
metabolic disorders such as hyperglycemia and dyslipidemia
(2). Lipoatrophic mice have virtually no white adipose tissue
and, as a consequence, severe hyperglycemia. Surgically
implanting adipose tissue markedly improves hyperglyce-
mia, hyperinsulinemia, and muscle insulin sensitivity (140).
Surgical removal of VAT through omentectomy plus ad-
justable gastric banding may improve glucose metabolism
(oral glucose tolerance, insulin sensitivity, and fasting glu-
cose and insulin levels) more than adjustable gastric banding
(141). Conversely, liposuction of SAT may not improve
CVD risk factors such as hyperglycemia, high blood pres-
sure, and dyslipidemia (142). Finally, antiretroviral therapy
sometimes results in human immunodeficiency virus lipo-
dystrophy. Despite weight loss, patients may experience
insulin resistance and dyslipidemia, which may be due to the
greater loss of SAT relative to VAT (143).
Cardiovascular clinical trial paradox. Adiposopathy may
also help explain why overweight patients with elevated
markers of inflammation and no major cardiovascular risk
factors may, paradoxically, not be “healthy.” The JUPITER
(Justification for the Use of Statins in Primary Prevention:
An Intervention Trial Evaluating Rosuvastatin) trial was a
landmark CVD outcome trial of 17,802 “apparently healthy
men and women” with low-density lipoprotein cholesterol
levels 130 mg/dl and high-sensitivity C-reactive protein
levels 2.0 mg/l who were randomized to rosuvastatin 20
mg/day or placebo. The conclusion was that rosuvastatin
significantly reduced CVD in “apparently healthy persons
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C-reactive protein levels” (144). However, baseline median
BMI was 28 kg/m2 (a BMI 25 kg/m2 is considered
overweight; a BMI 27 mg/m2 with comorbidities is a
utoff point to consider weight-loss drug therapy) (145).
lso at baseline, metabolic syndrome was present in 41% of
tudy participants. One interpretation of the study results
as that elevated C-reactive protein is not only a marker of
ascular inflammation, but also plays a direct role in the
athogenesis of atherosclerosis and thrombosis (146,147).
n alternative interpretation is that adiposopathy (a “dis-
ase”) was present at baseline in many study participants, as
upported by the high mean BMI, the high percentage of
tudy participants with metabolic syndrome, and the ele-
ated C-reactive protein. The latter is supported by the
ndings that C-reactive protein may be directly released
rom adipose tissue (148). Perhaps more importantly, ex-
essive body fat increases adipose tissue release of
nterleukin-6 (2), which stimulates increased C-reactive
rotein production from the liver (2,4). It seems plausible
hat the increased C-reactive protein level found among
any JUPITER study participants was significantly due to
athogenic adipose tissue immune responses. Thus, within
he adiposopathic paradigm, many of the study participants
ere not “healthy persons.” Many study participants had
vidence of adiposopathy, which may directly and indirectly
romote CVD. Finally, it is of interest that a reduction in
nflammatory markers (e.g., interleukin-6, C-reactive pro-
ein) with statins may, in part, be due to statin-induced
eductions in adipose tissue inflammation (149,150).
onclusions
diposopathy or “sick fat” is a cardiovascular disease.
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